Melinta Therapeutics

KIMYRSA

Manufacturer:

Melinta Therapeutics

Kimyrsa HCPCS:

J2406

HCPCS Code Descriptor:

Injection, oritavancin (kimyrsa), 10 mg

Category:

J Code

Kimyrsa NDCs:

70842-0225-01

Primary Type:

Antibiotic

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Kimyrsa:

KIMYRSA is an Antibiotic drug manufactured by Melinta Therapeutics and administered via the Intravenous route of administration. The J Code: J2406 is aligned to the drug KIMYRSA.

KIMYRSA is an anti-bacterial drug designed to treat acute bacterial and skin structure infections caused by Gram positive bacteria. As a lipoglycopeptide, KIMYRSA (J2406) uses three separate actions to kill bacterial cells. It inhibits cell wall biosynthesis, inhibits crosslinking in the bacterial cell wall by binding to peptides, and disrupts bacterial cell membrane integrity, ultimately leading to cell death. Hepatic insufficiency and usage of a drug that is metabolized by a CYP450 enzyme are contraindicated for use of KIMYRSA. Patient assistance can be found through Kimyrsa.

ACCESS PRICING AND MORE BY REGISTERING

J2406 Added Date:

October 1, 2021

J2406 Effective Date:

October 1, 2021

J2406 Termination Date:

HCPCS Active

Kimyrsa billing and coding information can be found through Melinta Therapeutics at the link below:
Kimyrsa patient assistance information can be found through the Kimrysa Support Program at the URL: https://kimyrsa.com/support-programs/
KIMYRSA prescribing information can be found at the link below:
Our team has not yet identified a source of side effects information for KIMYRSA. Please check back in a few weeks.